Jennifer Lachey - 11 Apr 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
11 Apr 2022
Net transactions value
-$331,115
Form type
4
Filing time
13 Apr 2022, 16:36:15 UTC
Previous filing
06 Apr 2022
Next filing
13 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $1,590 +5,300 +6.2% $0.3000* 91,000 11 Apr 2022 Direct
transaction KROS Common Stock Sale $86,961 -1,417 -1.6% $61.37 89,583 11 Apr 2022 Direct F1, F2
transaction KROS Common Stock Sale $62,881 -1,009 -1.1% $62.32 88,574 11 Apr 2022 Direct F1, F3
transaction KROS Common Stock Sale $147,002 -2,315 -2.6% $63.50 86,259 11 Apr 2022 Direct F1, F4
transaction KROS Common Stock Sale $35,860 -559 -0.65% $64.15 85,700 11 Apr 2022 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -5,300 -6.9% $0.000000 71,405 11 Apr 2022 Common Stock 5,300 $0.3000 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.97 to $61.935 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5).
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.975 to $62.97 inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.975 to $63.865 inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.00 to $64.49 inclusive.
F6 Immediately exercisable.